The Abbreviated Review pathway has been developed by the National Pharmaceutical Regulatory Agency of Malaysia.
This pathway can be used where The scope for product registration according to abbreviated and verification review only applies to new drug products and biologics including biosimilars. .
When relevant, the agency relies on prior decisions from EU-EMA United States WHO
120 working days for both new drug products and biologics.